近期注射吸毒者中丙型肝炎病毒再感染率高:TraP Hep C项目——一项前瞻性全国人群研究
冰岛TraP Hep C项目于2016年启动,为丙型肝炎病毒感染者提供直接抗病毒药物治疗。该前瞻性全国队列纳入2016年2月1日至2018年11月20日间估计获得持续病毒学应答的治愈患者,随访至2019年11月20日,共614例患者640次治疗获得治愈,确认50例患者发生52次再感染,再感染率为7.7/100人年。
要点
- 614例患者640次治疗获得治愈,随访672.1人年,确认52次再感染(50例患者)。
- 再感染率为7.7/100人年,中位再感染时间为232天。
- 多变量Cox模型显示年龄(HR 0.96)和近期注射吸毒(HR 2.91)与再感染风险显著相关。
核心结论
- 在广泛使用兴奋剂的环境中再感染率较高,尤其是近期注射吸毒的年轻人。
- 在高风险人群中定期随访对于早期诊断再感染和减少传播很重要。
研究设计与样本
- 前瞻性全国人群研究,纳入2016年2月1日至2018年11月20日间估计获得持续病毒学应答的HCV治愈患者,随访至2019年11月20日。
- 共640次治疗、614例患者(417例男性;平均年龄44.3岁)获得治愈。
- 采用单随机点插补法结合蒙特卡洛模拟估计观察期和再感染时间,再感染率以每100人年表示。
主要发现
- 共确认52次再感染,发生于50例患者(37例男性)。
- 随访672.1人年,中位再感染时间为232天。
- 523例患者(84.8%)报告有注射吸毒史,220次治疗(34.4%)为近期注射吸毒。
- 在有注射吸毒史的患者中,85.5%首选注射兴奋剂。
- 再感染率为7.7/100人年。
关键数值与推荐
- 多变量Cox比例风险模型(区间删失数据)显示,年龄与再感染风险显著相关(HR 0.96,95%CI 0.94-0.99)。
- 近期注射吸毒与再感染风险显著相关(HR 2.91,95%CI 1.48-5.76)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Treatment as Prevention for Hepatitis C program started in 2016 in Iceland, offering treatment with direct-acting antivirals to hepatitis C virus (HCV)-infected individuals. Reinfections through injection drug use (IDU) can hamper elimination efforts. We determined reinfection rates of HCV among patients in the program. METHODS: Clinical data were gathered prospectively. The study cohort consisted of HCV-cured patients with an estimated sustained virologic response between 1 February 2016 and 20 November 2018, with follow-up until 20 November 2019. The observation period and time until reinfection was estimated using a single random point imputation method coupled with Monte Carlo simulation. The reinfection rates were expressed as reinfections per 100 person-years (PY). RESULTS: In total, 640 treatments of 614 patients (417 male; mean age, 44.3 years) resulted in cure, with 52 reinfections subsequently confirmed in 50 patients (37 male). Follow-up was 672.1 PY, with a median time to reinfection of 232 days. History of IDU was reported by 523 patients (84.8%) and recent IDU with 220 treatments (34.4%). Stimulants were the preferred injected drug in 85.5% of patients with a history of IDU. The reinfection rate was 7.7/100 PY. Using multivariate Cox proportional hazards models for interval-censored data, age (hazard ratio, 0.96 [95% confidence interval, .94-.99]) and recent IDU (2.91 [1.48-5.76]) were significantly associated with reinfection risk. CONCLUSIONS: The reinfection rate is high in a setting of widespread stimulant use, particularly in young people with recent IDU. Regular follow-up is important among high-risk populations to diagnose reinfections early and reduce transmission. CLINICAL TRIALS REGISTRATION: NCT02647879.
引用
- Johannesson JM, Fridriksdottir RH, Löve TJ, et al. High Rate of Hepatitis C Virus Reinfection Among Recently Injecting Drug Users: Results From the TraP Hep C Program-A Prospective Nationwide, Population-Based Study. Clin Infect Dis. 2022. PMID: 35438144. doi:10.1093/cid/ciac272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。